Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2010

01-09-2010

Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function

Author: Garth L. Nicolson

Published in: Cancer and Metastasis Reviews | Issue 3/2010

Login to get access

Abstract

Cancer-associated fatigue is one of the most common symptoms in all forms and stages of cancer, yet scant attention is usually given to patients who have symptomatic complaints of fatigue. Cancer-associated fatigue is also associated with cellular oxidative stress, and during cancer therapy, excess drug-induced oxidative stress can limit therapeutic effectiveness and cause a number of side effects, including fatigue, nausea, vomiting, and more serious adverse effects. Cancer-associated fatigue and the chronic adverse effects of cancer therapy can be reduced by lipid replacement therapy using membrane lipids along with antioxidants and enzymatic cofactors, such as coenzyme Q10, given as food supplements. Administering these nutraceutical supplements can reduce oxidative membrane damage and restore mitochondrial and other cellular functions. Recent clinical trials using cancer and non-cancer patients with chronic fatigue have shown the benefits of lipid replacement therapy in reducing fatigue and restoring mitochondrial electron transport function.
Literature
1.
Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., et al. (2007). Cancer-related fatigue: The scale of the problem. The Oncologist, 12, 4–10.PubMedCrossRef
2.
Brown, L. F., & Kroenke, K. (2009). Cancer-related fatigue and its association with depression and anxiety: A systematic review. Psychosomatics, 50, 440–447.PubMedCrossRef
3.
Prue, G., Rankin, J., Allen, J., et al. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42, 846–863.PubMedCrossRef
4.
Curt, G. A., Breitbart, W., Cella, D., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. The Oncologist, 5, 353–360.PubMedCrossRef
5.
Respini, D., Jacobsen, P. B., Thors, C., et al. (2003). The prevalence and correlates of fatigue in older cancer patients. Critical Reviews in Oncology/Hematology, 47, 273–279.PubMedCrossRef
6.
Sood, A., & Moynihan, T. J. (2005). Cancer-related fatigue: An update. Current Oncology Reports, 7, 277–282.PubMedCrossRef
7.
Arnold, L. M. (2008). Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics, 49, 185–190.PubMedCrossRef
8.
Bender, C. M., Engberg, S. J., Donovan, H. S., et al. (2008). Symptom clusters in adults with chronic health problems and cancer as a comorbidity. Oncology Nursing Forum, 35, E1–E11.PubMedCrossRef
9.
Smets, E. M. A., Garssen, B., Cull, A., et al. (1996). Applications of the Multidimensional Fatigue Inventory (MFI-20) in cancer patients receiving radiotherapy. British Journal of Cancer, 73, 241–245.PubMed
10.
Stone, P., Hardy, J., Huddart, R., et al. (2000). Fatigue in patients with prostate cancer receiving hormone therapy. European Journal of Cancer, 36, 1134–1141.PubMedCrossRef
11.
Cella, D., Davis, K., Breitbart, W., et al. (2001). Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19, 3385–3391.PubMed
12.
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. The Lancet, 362(9384), 640–650.CrossRef
13.
14.
Manzullo, E. F., & Escalante, C. P. (2002). Research into fatigue. Hematology/Oncology Clinics of North America, 16, 619–628.PubMedCrossRef
15.
Given, B., Given, C., Azzouz, F., & Stommel, M. (2001). Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nursing Research, 50, 222–232.PubMedCrossRef
16.
Vogelzang, N., Breitbart, W., Cella, D., et al. (1997). Patient caregiver and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Seminars in Hematology, 34(Suppl 2), 4–12.PubMed
17.
Liu, L., Marler, M. R., Parker, B. A., et al. (2005). The relationship between fatigue and light exposure during chemotherapy. Supportive Care in Cancer, 13, 1010–1017.PubMedCrossRef
18.
Marrow, G. R. (2007). Cancer-related fatigue: Causes, consequences and management. The Oncologist, 12(suppl 1), 1–3.CrossRef
19.
Morrison, J. D. (1980). Fatigue as a presenting complaint in family practice. The Journal of Family Practice, 10, 795–801.PubMed
20.
Kroenke, K., Wood, D. R., Mangelsdorff, A. D., et al. (1988). Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA, 260, 929–934.PubMedCrossRef
21.
McDonald, E., David, A. S., Pelosi, A. J., & Mann, A. H. (1993). Chronic fatigue in primary care attendees. Psychological Medicine, 23, 987–998.PubMedCrossRef
22.
Kehrer, J. P. (1993). Free radicals and mediators of tissue injury and disease. Critical Reviews in Toxicology, 23, 21–48.PubMedCrossRef
23.
24.
Dreher, D., & Junod, A. F. (1996). Role of oxygen free radicals in cancer development. European Journal of Cancer, 32A, 30–38.PubMedCrossRef
25.
Abidi, S., & Ali, A. (1999). Role of oxygen free radicals in the pathogenesis and etiology of cancer. Cancer Letters, 142, 1–9.CrossRef
26.
Stadtman, E. (2002). Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Radical Biology & Medicine, 32, 789.CrossRef
27.
28.
Bartsch, H., & Nair, J. (2004). Oxidative stress and lipid peroxidation-driven DNA-lesions in inflammation driven carcinogenesis. Cancer Detection and Prevention, 28, 385–391.PubMedCrossRef
29.
Castro, L., & Freeman, B. A. (2001). Reactive oxygen species in human health and disease. Nutrition, 17, 295–307.CrossRef
30.
Johnson, T. M., Yu, Z. X., Ferrans, V. J., et al. (1996). Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proceedings of the National Academy of Science USA, 93, 11848–11852.CrossRef
31.
Ghaffari, S. (2008). Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxidation and Redox Signaling, 10, 1923–1940.CrossRef
32.
Maes, M. (2009). Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Current Opinions in Psychiatry, 22, 75–83.CrossRef
33.
Maes, M., & Twisk, F. N. (2009). Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: Disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinology Letters, 30, 677–693.PubMed
34.
Barber, D. A., & Harris, S. R. (1994). Oxygen free radicals and antioxidants: A review. American Pharmacology, 34, 26–35.
35.
Sun, Y. (1990). Free radicals, antioxidant enzymes and carcinogenesis. Free Radical Biology & Medicine, 8, 583–599.CrossRef
36.
Fridovich, I. (1995). Superoxide radical and superoxide dismutases. Annual Review of Biochemistry, 64, 97–112.PubMedCrossRef
37.
Seifried, H. E., McDonald, S. S., Anderson, D. E., et al. (2003). The antioxidant conundrum in cancer. Cancer Research, 61, 4295–4298.
38.
Jagetia, G. C., Rajanikant, G. K., Rao, S. K., et al. (2003). Alteration in the glutathione, glutathione peroxidase, superoxide dismutase and lipid peroxidation by ascorbic acid in the skin of mice exposed to fractionated gamma radiation. Clinica Chimica Acta, 332, 111–121.CrossRef
39.
Schwartz, J. L. (1996). The dual roles of nutrients as antioxidants and prooxidants: Their effects on tumor cell growth. The Journal of Nutrition, 126, 1221S–1227S.PubMed
40.
Aeschbach, R., Loliger, J., Scott, B. C., et al. (1994). Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chemistry and Toxicology, 32, 31–36.CrossRef
41.
Tanaka, T. (1994). Cancer chemoprevention by natural products. Oncology Reports, 1, 1139–1155.
42.
Prasad, K. N., Cole, W. C., Kumar, B., et al. (2001). Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. Journal of the American College of Nutrition, 20, 450S–453S.PubMed
43.
Toyokuni, S., Okamoto, K., Yodio, J., et al. (1995). Persistent oxidative stress in cancer. FEBS Letters, 358, 1–3.PubMedCrossRef
44.
Ray, G., Batra, S., Shukla, N. K., et al. (2000). Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Research and Treatment, 59, 163–170.PubMedCrossRef
45.
Brown, N. S., & Bicknell, R. (2001). Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Research, 3, 323–327.PubMedCrossRef
46.
Klaunig, J. E., & Kamendulis, L. M. (2004). The role of oxidative stress in carcinogenesis. Annual Review of Pharmacology and Toxicology, 44, 239–267.PubMedCrossRef
47.
Tas, F., Hansel, H., Belce, A., et al. (2005). Oxidative stress in breast cancer. Medical Oncology, 22, 11–15.PubMedCrossRef
48.
Kang, D. H. (2002). Oxidative stress, DNA damage and breast cancer. AACN Clinical Issues, 13, 540–549.PubMedCrossRef
49.
Sikka, S. C. (2003). Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention—a mechanistic approach. Current Medicinal Chemistry, 10, 2679–2692.PubMedCrossRef
50.
Aydin, A., Arsova-Sarafinovska, Z., Sayal, A., et al. (2006). Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostate hyperplasia. Clinical Biochemistry, 39, 176–179.PubMedCrossRef
51.
Otamiri, T., & Sjodahl, R. (1989). Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer, 64, 422–425.PubMedCrossRef
52.
Oxdemirler, G., Pabucçoglu, H., Bulut, T., et al. (1989). Increased lipoperoxide levels and antioxidant system in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 124, 555–559.
53.
Asal, N. R., Risser, D. R., Kadamani, S., et al. (1990). Risk factors in renal cell carcinoma. I. Methodology, demographics, tobacco beverage use and obesity. Cancer Detection and Prevention, 11, 359–377.
54.
Gago-Dominguez, M., Castelao, J. E., Yuan, J. M., et al. (2002). Lipid peroxidation: A novel and unifying concept of the etiology of renal cell carcinoma. Cancer Causes & Control, 13, 287–293.CrossRef
55.
Manoharan, S., Kolanjiappan, K., Suresh, K., et al. (2005). Lipid peroxidation and antioxidants status in patients with oral squamous cell carcinoma. The Indian Journal of Medical Research, 122, 529–534.PubMed
56.
Seril, D. N., Liao, J., Yang, G. Y., et al. (2003). Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis, 34, 353–362.CrossRef
57.
Batcioglu, K., Mehmet, N., Ozturk, I. C., et al. (2006). Lipid peroxidation and antioxidant status in stomach cancer. Cancer Investigation, 24, 18–21.PubMedCrossRef
58.
Jaruga, P., Zastawny, T. H., Skokowski, J., et al. (1992). Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Letters, 341, 59–64.CrossRef
59.
Conklin, K. A. (2004). Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integrated Cancer Therapies, 3, 294–300.CrossRef
60.
Nicolson, G. L., & Conklin, K. A. (2008). Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clinical & Experimental Metastasis, 25, 161–169.CrossRef
61.
Conklin, K. A. (2000). Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutrition and Cancer, 37, 1–18.PubMedCrossRef
62.
63.
Hauptlorenz, S., Esterbauer, H., Moll, W., et al. (1985). Effects of the lipid peroxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochemical Pharmacology, 34, 3803–3809.PubMedCrossRef
64.
Gonzalez, M. J. (1992). Lipid peroxidation and tumor growth: An inverse relationship. Medical Hypotheses, 38, 106–110.PubMedCrossRef
65.
Schackelford, R. E., Kaufmann, W. K., & Paules, R. S. (2000). Oxidative stress and cell cycle checkpoint function. Free Radical Biology & Medicine, 28, 1387–1404.CrossRef
66.
Balin, A. K., Goodman, D. B. P., Rasmussen, H., et al. (1978). Oxygen-sensitive stages of the cell cycle of human diploid cells. The Journal of Cell Biology, 78, 390–400.PubMedCrossRef
67.
Kurata, S. (2000). Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. The Journal of Biological Chemistry, 275, 23413–23416.PubMedCrossRef
68.
Wei, Q., Frazier, M. L., & Levin, B. (2000). DNA repair: A double edge sword. Journal of the National Cancer Institute, 92, 440–441.PubMedCrossRef
69.
Fojo, T. (2001). Cancer, DNA repair mechanisms, and resistance to chemotherapy. Journal of the National Cancer Institute, 93, 1434–1436.PubMedCrossRef
70.
Zhen, W., Link, C. J., O'Connor, P. M., et al. (1992). Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Molecular and Cellular Biology, 12, 3689–3698.PubMed
71.
Lee, Y.-J., & Shacter, E. (1999). Oxidative stress inhibits apoptosis in human lymphoma cells. The Journal of Biological Chemistry, 274, 19792–19798.PubMedCrossRef
72.
Shacter, E., Williams, J. A., Hinson, R. M., et al. (2000). Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis. Blood, 96, 307–313.PubMed
73.
Hampton, M. B., Fadeel, B., & Orrenius, S. (1998). Redox regulation of the caspases during apoptosis. Annals of the New York Academy of Sciences, 854, 328–335.PubMedCrossRef
74.
Chandra, J., Samali, A., & Orrenius, S. (2000). Triggering and modulation of apoptosis by oxidative stress. Free Radical Biology & Medicine, 29, 323–333.CrossRef
75.
Greenberger, J. S., Kagan, V. E., Pearce, L., et al. (2001). Modulation of redox signal transduction pathways in the treatment of cancer. Antioxidants Redox Signaling, 3, 347–359.PubMedCrossRef
76.
Feinendegen, L. E., Pollycove, M., & Neumann, R. D. (2007). Whole-body responses to low-level radiation exposure: New concepts in mammalian radiobiology. Experimental Hematology, 35, 37–46.PubMedCrossRef
77.
Epperly, M. W., Gretton, J. E., Sikora, C. A., et al. (2003). Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiation Research, 160, 568–578.PubMedCrossRef
78.
Sabbarova, I., & Kanai, A. (2007). Targeted delivery of radioprotective agents to mitochondria. Molecular Interventions, 8, 295–302.
79.
Leach, J. K., Black, S. M., Schmidt-Ullrich, R. K., & Mikkelsen, R. B. (2002). Activation of constitutive nitric-oxide synthase activity is an early signaling event induced by ionizing radiation. The Journal of Biological Chemistry, 277, 15400–15406.PubMedCrossRef
80.
Conklin, K. A. (2005). Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integrated Cancer Therapies, 4, 110–130.CrossRef
81.
Lehninger, A. L. (1951). Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. The Journal of Biological Chemistry, 190, 345–359.PubMed
82.
Rasmussen, U. F., & Rasmussen, H. N. (1985). The NADH oxidase system (external) of muscle mitochondria and its role in the oxidation of cytoplasmic NADH. The Biochemical Journal, 229, 632–641.
83.
Nohl, H. (1987). Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. European Journal of Biochemistry, 169, 585–591.PubMedCrossRef
84.
Davies, K. J. A., & Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. Journal of Biological Chemistry, 261, 3060–3067.PubMed
85.
Doroshow, J. H., & Davies, K. J. A. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. The Journal of Biological Chemistry, 261, 3068–3074.PubMed
86.
Gille, L., & Nohl, H. (1997). Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radical Biology & Medicine, 23, 775–782.CrossRef
87.
Eaton, S., Skinner, R., Hale, J. P., et al. (2000). Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clinica Chimica Acta, 302, 1–9.CrossRef
88.
Karlsson, J., Folkers, K., Astrom, H., et al. (1986). Effect of adriamycin on heart and skeletal muscle coenzyme Q10 (CoQ10) in man. In K. Folkers & Y. Yamamura (Eds.), Biomedical and clinical aspects of coenzyme Q (Vol. 5, pp. 241–245). Amsterdam: Elsevier.
89.
Papadopoulou, L. C., & Tsiftsoglou, A. S. (1996). Effects of hemin on apoptosis, suppression of cytochrome C oxidase gene expression, and bone-marrow toxicity induced by doxorubicin. Biochemical Pharmacology, 52, 713–722.PubMedCrossRef
90.
Palmeira, C. M., Serrano, J., Kuehl, D. W., et al. (1997). Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochimica et Biophysica Acta, 1321, 101–106.PubMedCrossRef
91.
Brizel, D. M. (2007). Pharmacologic approaches to radiation protection. Journal of Clinical Oncology, 25, 4084–4089.PubMedCrossRef
92.
Domae, N., Sawada, H., Matsuyama, E., et al. (1981). Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treatment Reports, 65, 79–91.PubMed
93.
Usui, T., Ishikura, H., Izumi, Y., et al. (1982). Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicology Letters, 12, 75–82.PubMedCrossRef
94.
Judy, W. V., Hall, J. H., Dugan, W., et al. (1984). Coenzyme Q10 reduction of adriamycin cardiotoxicity. In K. Folkers & Y. Yamamura (Eds.), Biomedical and clinical aspects of coenzyme Q (Vol. 4, pp. 231–241). Amsterdam: North-Holland Biomedical.
95.
Cortes, E. P., Gupta, M., Chou, C., et al. (1978). Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treatment Reports, 62, 887–891.PubMed
96.
Buckingham, R., Fitt, J., & Sitzia, J. (1997). Patients’ experience of chemotherapy: Side-effects of carboplatin in the treatment of carcinoma of the ovary. European Journal of Cancer Care, 6, 59–71.PubMedCrossRef
97.
Iarussi, D., Auricchio, U., Agretto, A., et al. (1994). Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine, 15, S207–S212.PubMedCrossRef
98.
Loke, Y. K., Price, D., Derry, S., et al. (2006). Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. British Medical Journal, 232, 335–339.CrossRef
99.
Von Roenn, J. H., & Paice, J. A. (2005). Control of common, non-pain cancer symptoms. Seminars in Oncology, 32, 200–210.CrossRef
100.
Borneman, T., Piper, B. F., Sun, V. C., et al. (2007). Implementing the fatigue guidelines at one NCCN member institution: Process and outcomes. Journal of the National Comprehensive Cancer Network, 5, 1092–1101.PubMed
101.
Escalante, C. P., Kallen, M. A., Valdres, R. U., et al. (2010). Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. Journal of Pain and Symptom Management, 39, 691–701.PubMedCrossRef
102.
Ryan, J. L., Carroll, J. K., Ryan, E. P., et al. (2007). Mechanisms of cancer-related fatigue. The Oncologist, 12(Suppl. 1), 22–34.PubMedCrossRef
103.
Mustian, K. M., Morrow, G. R., Carroll, J. K., et al. (2007). Integrative nonpharmacological behavioral interventions for the management of cancer-related fatigue. The Oncologist, 12(Suppl. 1), 52–67.PubMedCrossRef
104.
Watson, T., & Mock, V. (2004). Exercise as an intervention for cancer-related fatigue. Physical Therapy, 84, 736–743.PubMed
105.
Zee, P. C., & Acoli-Isreal, S. (2009). Does effective management of sleep disorders reduce cancer-related fatigue? Drugs, 69(Suppl. 2), 29–41.PubMedCrossRef
106.
Milton, O., Richardson, A., Sharpe, M., et al. (2008). A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. Journal of the National Cancer Institute, 100, 1–12.
107.
Levy, M. (2008). Cancer fatigue: A review for psychiatrists. General Hospital Psychiatry, 30, 233–244.PubMedCrossRef
108.
Nicolson, G. L. (2003). Lipid replacement as an adjunct to therapy for chronic fatigue, anti-aging and restoration of mitochondrial function. Journal of the American Nutraceutical Association, 6(3), 22–28.
109.
Agadjanyan, M., Vasilevko, V., Ghochikyan, A., et al. (2003). Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. Journal of Chronic Fatigue Syndrome, 11(3), 23–26.CrossRef
110.
Nicolson, G. L. (2005). Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathology Oncology Research, 11, 139–144.PubMedCrossRef
111.
Wei, Y. H., & Lee, H. C. (2002). Oxidative stress, mitochondrial DNA mutation and impairment of antioxidant enzymes in aging. Experimental Biology and Medicine, 227, 671–682.PubMed
112.
Huang, H., & Manton, K. G. (2004). The role of oxidative damage in mitochondria during aging: A review. Frontiers in Bioscience, 9, 1100–1117.PubMedCrossRef
113.
Logan, A. C., & Wong, C. (2001). Chronic fatigue syndrome: Oxidative stress and dietary modifications. Alternative Medicine Review, 6, 450–459.PubMed
114.
Manuel, y, Keenoy, B., Moorkens, G., Vertommen, J., & De Leeuw, I. (2001). Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Science, 68, 2037–2049.CrossRef
115.
Richards, R. S., Roberts, T. K., McGregor, N. R., et al. (2000). Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Reports, 5, 35–41.
116.
Felle, S., Mecocci, P., Fano, G., et al. (2000). Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biology & Medicine, 29, 1252–1259.CrossRef
117.
Dianzani, M. U. (1993). Lipid peroxidation and cancer. Critical Reviews in Oncology/Hematology, 15, 125–147.PubMedCrossRef
118.
Pall, M. L. (2000). Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Medical Hypotheses, 54, 115–125.PubMedCrossRef
119.
Nicolson, G. L., Poste, G., & Ji, T. (1977). Dynamic aspects of cell membrane organization. Cell Surface Reviews, 3, 1–73.
120.
Subczynski, W. K., & Wisniewska, A. (2000). Physical properties of lipid bilayer membranes: Relevance to membrane biological functions. Acta Biochimica Polonica, 47, 613–625.PubMed
121.
Radi, R., Rodriguez, M., Castro, L., et al. (1994). Inhibition of mitochondrial electronic transport by peroxynitrite. Archives of Biochemistry and Biophysics, 308, 89–95.PubMedCrossRef
122.
Kanno, T., Sato, E. E., Muranaka, S., et al. (2004). Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radical Research, 38, 27–35.PubMedCrossRef
123.
Nicolson, G. L., & Ellithrope, R. (2006). Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. Journal of Chronic Fatigue Syndrome, 13(1), 57–68.CrossRef
124.
Ellithorpe, R. R., Settineri, R., & Nicolson, G. L. (2003). Reduction of fatigue by use of a dietary supplement containing glycophospholipids. Journal of the American Nutraceutical Association, 6(1), 23–28.
125.
Mansbach, C. M., & Dowell, R. (2000). Effect of increasing lipid loads on the ability of the endoplasmic reticulum to transport lipid to the Golgi. Journal of Lipid Research, 41, 605–612.PubMed
126.
Seidman, M., Khan, M. J., Tang, W. X., et al. (2002). Influence of lecithin on mitochondrial DNA and age-related hearing loss. Otolaryngology - Head and Neck Surgery, 127, 138–144.PubMedCrossRef
127.
Piper, B. F., Linsey, A. M., & Dodd, M. J. (1987). Fatigue mechanism in cancer. Oncology Nursing Forum, 14, 17–23.PubMed
128.
Nicolson, G. L., Ellithorpe, R. R., Ayson-Mitchell, C., et al. (2010). Lipid replacement therapy with a glycophospholipid–antioxidant–vitamin formulation significantly reduces fatigue within one week. Journal of the American Nutraceutical Association, 13(1), 11–15.
129.
Colodny, L., Lynch, K., Farber, C., et al. (2000). Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy. Journal of the American Nutraceutical Association, 2(1), 17–25.
Metadata
Title
Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function
Author
Garth L. Nicolson
Publication date
01-09-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9245-0

Other articles of this Issue 3/2010

Cancer and Metastasis Reviews 3/2010 Go to the issue

OriginalPaper

Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals

OriginalPaper

Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer

ReviewPaper

Cancer and metastasis: prevention and treatment by green tea

OriginalPaper

Inhibition of cancer cell invasion and metastasis by genistein

OriginalPaper

Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis

ReviewPaper

Do nutraceutics play a role in the prevention and treatment of colorectal cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits